
Redan Pharmaceuticals Private Limited
Founded in 2008 and headquartered in Chandigarh, India.
Founded in 2008 and headquartered in Chandigarh, India.
Chandigarh, India
+91-XXXXXXXXXX
U24119CH2008PTC031305
031305
Private Limited Indian Non-Government Company
15 Jul 2008
30 Sep 2018
31 Mar 2018
Unlisted
Roc Chandigarh
Name | Designation | Appointment Date | Status |
---|---|---|---|
Arunaksh Bhardwaj ![]() | Director | 15-Jul-2008 | Current |
Rajesh Bhardwaj ![]() | Director | 15-Jul-2008 | Current |
Redan Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
In 2017, Redan Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Rajesh Bhardwaj is a mutual person
Rajesh Bhardwaj is a mutual person
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Redan Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Redan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Redan Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Redan Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2018 as per latest MCA records.
Redan Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2018 with Roc Chandigarh.
Arunaksh Bhardwaj was appointed as a Director was appointed as a Director on 15 Jul 2008 & has been associated with this company since 16 years 9 months .
Rajesh Bhardwaj was appointed as a Director was appointed as a Director on 15 Jul 2008 & has been associated with this company since 16 years 9 months .
Redan Pharmaceuticals Private Limited was registered on 15 Jul 2008 with Roc Chandigarh & aged 16 years 9 months as per MCA records.
Redan Pharmaceuticals Private Limited was incorporated on 15 Jul 2008.
The authorized share capital of Redan Pharmaceuticals Private Limited is ₹ 0.50 M and paid-up capital is ₹ 0.15 M.
Currently 2 directors are associated with Redan Pharmaceuticals Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Redan Pharmaceuticals Private Limited is Plot No. 73 Ground Floor Industrial Area Phase-2, India, Chandigarh, 160002.
The corporate identification number (CIN) of Redan Pharmaceuticals Private Limited is U24119CH2008PTC031305 and the company number is 031305 as per Ministry of Corporate Affairs (MCA).
The most recent Balance Sheet for Redan Pharmaceuticals Private Limited was filed with the ROC on 31 Mar 2018.
Search company & director profiles for free and gain access to critical business data.
MA